源自丙酮丁醇梭菌的微生物多肽在制备抗肿瘤疫苗中的应用
By cross-reacting the microbial polypeptide SLVDYGFRL derived from Clostridium acetonebutanol with the TP53G105V mutant tumor-specific antigen YQVSYGFRL, an anti-tumor vaccine was prepared, solving the problems of existing tumor vaccines being difficult to scale up and personalize, and achieving broad-spectrum applicability and high-efficiency anti-tumor effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HARBIN MEDICAL UNIVERSITY
- Filing Date
- 2026-03-27
- Publication Date
- 2026-07-17
AI Technical Summary
Existing tumor vaccines are difficult to mass-produce and widely apply. Traditional TSA vaccines are costly to customize individually, and microbial peptide screening is difficult, making it hard to find universal peptides suitable for different individuals.
Using the microbial polypeptide SLVDYGFRL derived from Clostridium acetone-butanol, which has amino acid sequence homology with the tumor-specific antigen polypeptide YQVSYGFRL generated by the TP53G105V mutation, T cells are induced to produce a specific cross-immune response. This is suitable for various tumor types carrying the TP53G105V mutation and can be prepared as an anti-tumor vaccine.
It significantly improves the activation efficiency of CD8+ T cells, enabling large-scale production and broad-spectrum clinical application of the vaccine. It has dual application potential for treatment and prevention, is applicable to at least 14 types of cancer, reduces immune tolerance, and enhances the body's immune surveillance ability against potential tumors.
Smart Images
Figure CN121944093B_ABST